M E Davis, D G Harrison. Show Affiliations »
Abstract
Entities: Chemical
Mesh： See more » Arteriosclerosis/metabolismArteriosclerosis/prevention & controlArteriosclerosis/therapyCaveolin 1Caveolins/metabolismCell Division/drug effectsCholesterol/metabolismCysteine Proteinase Inhibitors/pharmacologyEndothelium, Vascular/drug effectsEndothelium, Vascular/metabolismGTP-Binding Proteins/metabolismHumansHydroxymethylglutaryl CoA Reductases/metabolismHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic useHypercholesterolemia/drug therapyHypercholesterolemia/metabolismMuscle, Smooth, Vascular/drug effectsMuscle, Smooth, Vascular/metabolismNitric Oxide/biosynthesisNitric Oxide Synthase/metabolismNitric Oxide Synthase Type IIIPolyisoprenyl Phosphates/metabolismSesquiterpenesSignal Transduction/drug effectsSuperoxides/metabolism
Substances： See more » CAV1 protein, humanCaveolin 1CaveolinsCysteine Proteinase InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsPolyisoprenyl PhosphatesSesquiterpenesSuperoxidesNitric Oxidefarnesyl pyrophosphateCholesterolHydroxymethylglutaryl CoA ReductasesNOS3 protein, humanNitric Oxide SynthaseNitric Oxide Synthase Type IIIGTP-Binding Proteinsgeranylgeranyl pyrophosphate
Year: 2001 PMID： 11136674 DOI： 10.1161/01.cir.103.1.2
Source DB: PubMed Journal: Circulation ISSN： 0009-7322 Impact factor: 29.690